期刊文献+

CD33+HLA—DR-髓源抑制性细胞在肾癌患者外周血中的表达及临床意义

原文传递
导出
摘要 目的:探讨CD33+HLA—DR-髓源抑制性细胞在肾癌患者外周血中的表达及临床意义。方法:随机选取2010年1月~2014年12月我院收治的肾癌患者40例及健康志愿者20例外周血,均行流式细胞术检测外周血中CD33+HLA—DR-髓源抑制性细胞水平,探讨与肿瘤病理类型、进展之间的关系。结果:肾癌患者外周血中CD33+HLA—DR-髓源抑制性细胞表达水平为(1.90±0.12)%,明显高于健康组的(0.61±0.12)%,差异明显(P〈0.05);按照肿瘤分期,Iv期患者外周血中CD33+HLA—DR-髓源抑制性细胞水平高于I期、II期及III期,差异明显(P〈0.05);外周血中CD33+HLA—DR-髓源抑制性细胞表达水平与年龄、性别无关。结论:在肾癌患者外周血中,CD33+HLA—DR-髓源抑制性细胞表达水平与肿瘤分期、病理分型明显相关,可为患者预后、肿瘤免疫提供参考。
作者 李春
出处 《医学与社会》 2015年第B05期47-47,共1页 Medicine and Society
  • 相关文献

参考文献4

  • 1Nagaraj S, Gabrilovich DI. Myeloid - derived suppressor cells in human cance[ J]. Cancer J, 2010, 16(4): 348-53.
  • 2奉松青,刘春晓,郑少波,黄鹏,陈玢屾,郭凯.肾癌患者外周血中CD33^+HLA-DR^-髓源抑制性细胞的表达及其临床意义[J].南方医科大学学报,2013,33(4):550-553. 被引量:5
  • 3奉青松.CD33+HIJA-DR-髓源抑制性细胞在肾癌患者外周血中的表达及临床意义[D].南方医科大学,2013.
  • 4Porembka MR, Mitchem JB, Belt BA, et al. Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid - derived suppressor cells which promote prima- ry tumor growth[J]. Cancer Immunol Immunother, 2012, 61(09) : 1373 -1385.

二级参考文献14

  • 1Porembka MR, Mitchem JB, Belt BA, et al. Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid- derived suppressor cells which promote primary tumor growth [J]. Cancer Immunol Immunother, 2012, 61(9): 1373-85.
  • 2Gabitass RF, Annels NE, Stocken DD, et al. Elevated myeloid- derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13 [J]. Cancer Immunol Immunother, 2011, 60(10): 1419-30.
  • 3Diaz-Montero CM, Salem ML, Nishimura MI, et al. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin- cyclophosphamide chemotherapy[J]. Cancer Immunol Immunother, 2009, 58(1): 49-59.
  • 4Nagaraj S, Gabrilovich DI. Myeloid-derived suppressor cells in human cancer[J]. Cancer J, 2010, 16(4): 348-53.
  • 5Talmadge JE. Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy[J]. Clin Cancer Res, 2007, 13(18 Pt 1): 5243-8.
  • 6Ko JS, Zea AH, Rini BI, et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients[J]. Clin Cancer Res, 2009, 15(6): 2148-57.
  • 7Nagaraj S, Gabrilovich DI. Myeloid-derived suppressor cells [J]. Adv Exp Med Biol, 2007, 601: 213-23.
  • 8Zhao F, Obermann S, von Wasielewski R, et al. Increase in frequency of myeloid-derived suppressor cells in mice with spontaneous pancreatic carcinoma[J]. Immunology, 2009, 128(1): 141-9.
  • 9Ueha S, Shand FH, Matsushima K. Myeloid cell population dynamics in healthy and tumor-bearing mice [J]. Int Immunopharmacol, 2011, 11(7): 783-8.
  • 10Badn W, Bronte V. Myeloid-derived suppressor cells in cancer[M]// Wang R. Innate immune regulation and cancer immunotherapy. New York: Springer, 2012: 217-29.

共引文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部